Genomics

Dataset Information

0

Canakinumab treatment in hyperimmunoglobulinemia D with periodic fever syndrome


ABSTRACT: Objective. To evaluate the efficacy and safety of canakinumab treatment in active hyperimmunoglobulinemia D with periodic fever syndrome (HIDS). Methods. This is a 3-part open-label study with a 6-month treatment period (P1; 300 mg or 4 mg/kg q6w) a 6-month withdrawal period (P2) and a 24-month treatment period (P3). The primary endpoint was reduction in frequency of flares during treatment period compared with the historical period (HP; period in which patients did not receive drugs other than NSAIDs and/or steroids).

ORGANISM(S): Homo sapiens

PROVIDER: GSE97075 | GEO | 2018/09/17

REPOSITORIES: GEO

Similar Datasets

2011-06-20 | E-GEOD-17732 | biostudies-arrayexpress
2011-06-20 | GSE17732 | GEO
2019-01-11 | E-MTAB-6121 | biostudies-arrayexpress
2014-03-15 | GSE54926 | GEO
2016-05-19 | GSE81485 | GEO
2014-03-15 | E-GEOD-54926 | biostudies-arrayexpress
2023-12-17 | GSE235769 | GEO
2010-09-12 | GSE21611 | GEO
2010-09-12 | E-GEOD-21611 | biostudies-arrayexpress
| S-EPMC3581266 | biostudies-literature